Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Tests Global Manufacturing Process For CAR-T Therapy

Executive Summary

Rather than wait for regulatory approval prior to commercial-scale manufacturing, Novartis is proving out its global commercial manufacturing process for a CAR-T cell therapy in a Phase II clinical trial as questions remain on how to translate the manufacturing process from the research laboratory to the factory.

Advertisement

Related Content

CAR-T Therapies: Failure To Meet Release Specifications May Not Bar Patient Use
Argos Nears Phase III Results For Precision Cancer Immunotherapy
New Interim CAR-T Data Support Kite’s BLA Submission Plans
Novartis Cell Therapy Unit To Close: Implications For CAR-T Could Be Big
Novartis calls Dendreon 'an enabler, not a failure'

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS119211

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel